Nasa has signed an agreement to develop and commercialise a spray to fight motion sickness based on research developed for space flight.
The American space agency said it had conducted "extensive research" into the area to help its astronauts, who often experience such problems.
About 50% of astronauts experience motion sickness, Nasa said.
But it said its findings into the problem had culminated in a spray which was fast-acting and effective.
The drug, Scopolamine, is currently administered as a tablet or as an injection, but a spray formulation of the drug has been shown to be even more effective.
Under the Space Act Agreement, Nasa will work with Epiomed Therapeutics to formulate the drug into a commercial product for the treatment of acute and chronic motion sickness.
"Nasa and Epiomed will work closely together on further development of INSCOP to optimise therapeutic efficiency for both acute and chronic treatment of motion sickness which can be used by Nasa, the Department of Defense and world travellers on land, in the air and on the seas," said Lakshmi Putcha, developer of the innovative treatment strategy at Johnson Space Centre.
Epiomed is also working with the US Navy on the spray, but the company will still have to receive FDA approval before any drug can be sold.